


# **Clinical Provider Practice Tool**

# **Cognitive Impairment Identification**



for dementia screening, but many individuals with clinically meaningful cognitive impairment will score higher. When greater sensitivity is desired, a cut point of <4 is recommended as it may indicate a need for further evaluation of cognitive status. \*\*Neuropsychological evaluation is typically most helpful for differential diagnosis, determining nature and severity of cognitive functioning, and the development of an appropriate treatment plan. Testing is typically maximally beneficial in the following score ranges: SLUMS = 18–27 MoCA = 19–27 Kokmen STMS = 19–33 MMSE/MMSE-2 = 18–28

## **Dementia Work-Up**

Follow these diagnostic guidelines in response to patient failure on cognitive screening (e.g., Mini-Cog) or other signs of possible cognitive impairment.

## **History and Physical**

- Person-centered care includes understanding cultural context in which people are living (see www.actonalz. org/culturally-responsive-resources)
- Review onset, course, and nature of memory and cognitive deficits (Alzheimer's Association Family Questionnaire may assist) and any associated behavioral, medical or psychosocial issues
- Assess ADLs and IADLs, including driving and possible medication and financial mismanagement (Functional Activities Questionnaire and/or OT evaluation may assist)
- Conduct structured mental status exam (e.g., MoCA, SLUMS, MMSE)
- Assess mental health (consider depression, anxiety, chemical dependency)
- Perform neurological exam focusing on focal/lateralizing signs, vision, including visual fields, and extraocular movements, hearing, speech, gait, coordination, and evidence of involuntary or impaired movements

## **Diagnostics**

#### Lab Tests

- Routine: CBC, lytes, BUN, Cr, Ca, LFTs, glucose
- Dementia screening labs: TSH, B12
- Contingent labs (per patient history): RPR or MHA-TP, HIV, heavy metals

#### Neuroimaging

• CT or MRI when clinically indicated

## **Diagnosis\***

#### **Mild Cognitive Impairment**

- Mild deficit in one cognitive function: memory, executive, visuospatial, language, attention
- Intact ADLs and IADLs; does not meet criteria for dementia

#### **Alzheimer's Disease**

- Most common type of dementia (60–80% of cases)
- Memory loss, confusion, disorientation, dysnomia, impaired judgment/behavior, apathy/ depression

#### **Dementia With Lewy Bodies/Parkinson's Dementia**

- Second most common type of dementia (up to 30% of cases)
- Hallmark symptoms include visual hallucinations, REM sleep disorder, parkinsonism, and significant fluctuations in cognition

## **Follow-Up Diagnostic Visit**

- Include family members, friends, or other care partners
- Review intervention checklist for Alzheimer's disease and related dementias

### Neuropsychological Testing

- Indicated in cases of early or mild symptom presentation, for differential diagnosis, determination of nature and severity of cognitive functioning, and/or development of appropriate treatment plan
- Typically maximally beneficial in the following score ranges: MoCA 19-27; SLUMS 18-27; MMSE 18-28; Kokmen STMS 19-33

#### **Frontotemporal Dementia**

- Third most common type of dementia primarily affecting individuals in their 50s and 60s
- EITHER marked changes in behavior/personality OR language variant (difficulty with speech production or loss of word meaning)

#### **Vascular Dementia**

- Relatively rare in pure form (6-10% of cases)
- Symptoms often overlap with those of AD; frequently there is relative sparing of recognition memory

\* The latest DSM-5 manual uses the term "Major Neurocognitive Disorder" for dementia and "Mild Neurocognitive Disorder" for mild cognitive impairment. This ACT on Alzheimer's resource uses the more familiar terminology, as the new terms have yet to be universally adopted.

 Refer to the Alzheimer's Association 24/7 Helpline at 1-800-272-3900 and/or the Eldercare Locator at 1-800-677-1116

Dementia Management	
Diagnostic Uncertainty & Behavior Management	<ul> <li>Refer to Specialist as Needed</li> <li>Neurologist (dementia focus, if possible)</li> <li>Geriatric Psychiatrist</li> <li>Geriatrician</li> <li>Memory Disorders Clinic</li> </ul>
Counseling, Education, Support & Planning	<ul> <li>Family Meeting</li> <li>Refer to social worker or care coordinator</li> <li>Link to Community Resources</li> <li>Refer to the Alzheimer's Association 24/7 Helpline at 1-800-272-3900 and/or the Eldercare Locator at 1-800-677-1116</li> <li>Resources for diverse populations: www.actonalz. org/screening-diverse-populations</li> <li>Provide After a Diagnosis<sup>1</sup></li> <li>Provide Taking Action Workbook<sup>6</sup></li> </ul>
Stimulation / Activity / Maximizing Function	<ul> <li>Daily Mental, Physical and Social Activity</li> <li>Provide Living Well Workbook<sup>5</sup> (includes nonpharm therapies for early to mid stage)</li> <li>Adult day services (mid to late stage)</li> <li>Sensory aids (hearing aids, pocket talker, glasses)</li> </ul>
<b>Safety</b> Note: Individuals with dementia are vulnerable adults and may be at a higher risk for elder abuse.	<ul> <li>Driving <ul> <li>Counsel on risks</li> <li>Refer for driving evaluation<sup>2</sup></li> <li>Provide At the Crossroads<sup>3</sup></li> </ul> </li> <li>Medication Management <ul> <li>Family oversight or health care professional</li> </ul> </li> <li>Financial / Legal <ul> <li>Encourage patient to assign durable power of attorney; elder law attorney as needed</li> </ul> </li> </ul>
Advance Care Planning	<ul> <li>Complete Advance Care Plan</li> <li>Refer to advance care planning facilitator within system, if available</li> <li>Encourage completion of healthcare directive forms<sup>4</sup></li> </ul>
Medications	<ul> <li>Memory: Donepezil, rivastigmine patch, galantamine and memantine (mid-late stage)</li> <li>Mood &amp; Behavior: SSRIs or SNRIs</li> <li>Avoid/Minimize: Anticholinergics, hypnotics, narcotics, and antipsychotics (not to be used in Lewy Body dementia)</li> </ul>

## Tools

#### Mini-Cog

- Public domain: www.mini-cog.com
- Sensitivity for dementia: 76-99%
- Specificity: 89-93%

#### Montreal Cognitive Assessment (MoCA)

- Public domain: www.mocatest.org/
- Sensitivity: 90% for MCI, 100% for dementia
- Specificity: 87%

#### St. Louis University Mental Status (SLUMS)

- Public domain: http://medschool.slu.edu/ agingsuccessfully/pdfsurveys/slumsexam\_05.pdf
- Sensitivity: 92% for MCI, 100% for dementia
- Specificity: 81%

## **Dementia Management Resources**

- 1. After a Diagnosis www.dfamerica.org/provider-tools/
- 2. American Occupational Therapy Association myaota.aota.org/driver\_search/index.aspx
- 3. At the Crossroads: Family Conversations About Alzheimer's Disease, Dementia & Driving www.thehartford.com/alzheimers

#### **Measure/Assess IADLs**

 http://consultgeri.org/try-this/dementia/ issue-d13.pdf

#### **Family Questionnaire**

www.actonalz.org/pdf/Family-Questionnaire.pdf

#### **Mini-Mental Status Exam (MMSE)**

- Copyrighted: www4.parinc.com/Products/ Product.aspx?ProductID=MMSE
- Sensitivity: 18% for MCI, 78% for dementia
- Specificity: 100%

 National Hospice & Palliative Care Organization Download state-specific advance directive forms at www.caringinfo.org

#### 5. Living Well Workbook

www.alz.org/mnnd/documents/15\_ALZ\_Living\_ Well\_Workbook\_Web.pdf

#### 6. Taking Action Workbook

www.alz.org/i-have-alz/downloads/lwa\_pwd\_ taking\_action\_workbook.pdf

## **References: Provider Checklist**

Borson, S., Scanlan, J.M., Chen, P., & Ganguli, M. (2003). The Mini-Cog as a screen for dementia: Validation in a population-based sample. JAGS, 51(10), 1451-1454.

Borson S, Scanlan JM, Watanabe J et al. Improving identification of cognitive impairment in primary care. Int J Geriatr Psychiatry 2006; 21: 349–355.

Ismail Z, Rajii TK, Shulman KI. Brief cognitive screening instruments: an update. Int J Geriatr Psychiatry. Feb 2010; 25(2):111-20.

Larner, AJ. Screening utility of the Montreal Cognitive Assessment (MoCA): in place of – or as well as – the MMSE? Int Psychogeriatr. Mar 2012;24(3):391-6.

Lessig M, Scanlan J et al. Time that tells: Critical clock-drawing errors for dementia screening. Int Psychogeriatr. 2008 June; 20(3): 459–470.

McCarten J, Anderson P et al. Screening for cognitive impairment in an elderly veteran population: Acceptability and results using different versions of the Mini-Cog. J Am Geriatr Soc 2011; 59: 309-213. McCarten J, Anderson P et al. Finding dementia in primary care: The results of a clinical demonstration project. J Am Geriatr Soc 2012; 60: 210-217.

Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. Apr 2005;53(4):695-699.

Scanlan J & Borson S. The Mini-Cog: Receiver operating characteristics with the expert and naive raters. Int J Geriatr Psychiatry 2001; 16: 216-222.

Tariq SH, Tumosa N, Chibnall JT, et al. Comparison of the Saint Louis University mental status examination and the mini-mental state examination for detecting dementia and mild neurocognitive disorder-a pilot study. Am J Geriatr Psychiatry. Nov 2006;14(11):900-10.

Tsoi K, Chan J et al. Cognitive tests to detect dementia: A systematic review and meta-analysis. JAMA Intern Med. 2015; E1-E9.



www.ACTonALZ.org